Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02081118 on ClinicalTrials.gov · last registry update 2016-08-09

Finished March 2015, after enrolling 209 people. Primary outcome, as filed: Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Hanmi Pharmaceutical Company Limited
Sponsor type: Industry
Enrollment: 209
Started: 2014-02
Primary completion: 2015-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in baseline in glycosylated haemoglobin (HbA1c) at 16 weeks

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.